

	Indicator	Definition	Numerator	Denominator	Service Level	Use/Interpretation	Type	Category	Frequency
1	Proportion of patients screened with CD4 amongst eligible (newly tested HIV +; returnees after LTF; VL above threshold; AHD danger signs)	Proportion of patients identified as eligible for CD4 (potential AHD) testing who had the test done	Number CD4 done amongst eligible patients	Total number patients eligible for targeted CD4	IPD/OPD	Identifies suspected AHD amongst patients unstable on ART or newly tested HIV+	Minimum	Quality of service	Quarterly
2	Proportion of patients with CD4<200 screened for TB (LAM) (by CD4<100 <200)	Proportion of patients with a CD4 <200 screened for TB	Number of TB LAM tests CD4<200	Tot patient with CD4< 200	IPD/OPD	Tracks whether TB screening (LAM) is being done according to guidelines	Minimum	Quality of service	Quarterly
3	Proportion of patients TB (LAM) positive (by CD4<100 and CD4<200)	Proportion of patients with CD4 <200 identified with TB using LAM test	Number TB LAM positive CD4<200	Tot number screened for TB (LAM)	IPD/OPD	This shows the number of TB cases identified by LAM amongst patients with AHD. Used for	Minimum	Quality of service	Quarterly
4	TB (LAM) diagnosis in CD4>200	Additional TB (LAM) diagnosis (CD4>200)	Number of TB LAM CD4>200	Tot New Stage 3 or 4 and/or unstable with CD4>200	IPD/OPD	Confirmation of TB suspicion			
5	Proportion of patients TB (LAM) positive with CD4>200	Proportion of patients CD4 >200 identified with TB using LAM test	Number of TB LAM positive CD4>200	Tot number screened for TB (LAM)	IPD/OPD	This shows the number of TB cases identified by LAM amongst patients with AHD. Used for	Minimum	Quality of service	Quarterly
6	Proportion of patients LAM + started on TB treatment	TB treatment initiations	Tot patients started on TB amongst LAM +	Tot number diagnosed with TB (LAM +)	IPD/OPD	Yield of LAM tests			
7	Proportion of patients with CD4<100 screened for serum CrAg	Proportion of patients with CrAg done amongst patients with CD4<100	Number of patients with CD4<100 with Serum CrAg done	Tot number of patients with CD4 <100	IPD/OPD	Tracks whether serum CrAg screening amongst eligible is according to guidelines	Minimum	Quality of service	Quarterly
8	Proportion serum CrAg positive amongst amongst serum CrAg done	This identifies the number of diagnoses of serum cryptococcosis	Tot number of patients serum CrAg +ve	Tot number of patients with Serum CrAg done	IPD/OPD	Identifies number of patients with serum CrAg in patients with CD4<100	Minimum	Quality of service	Quarterly
9	Proportion of serum CrAg" patients subsequently screened for Cryptococcal Meningitis	Proportion of serum CrAg + patients who had an LP	Tot patients serum CrAg+ with a LP	Tot number patients Serum CrAg positive	IPD/ RAU	Measures effectiveness of referrals for LP amongst CM suspects			
10	Proportion of patients diagnosed with Crypto Meningitis	Proportion of patients CSF CrAg +	Total CSF CrAg positive	Total screened for Crypto by CSF-CrAg	IPD/OPD	Identifies CM among serum CrAg +			
11	Proportion of patients CrAg + started on CM treatment	CM treatment initiations	Tot patients started on CM Rx amongst CSF-CrAg +	Tot number diagnosed with CM	IPD/OPD	Clinical outcome of CrAg tests			
12	Proportion of patients with AHD dying within 48 hrs of admission (In hospital mortality)	Proportion of patients with AHD dying within 48 h after admission amongst all AHD admissions	Total number patients with AHD dying within 48 hrs of admission	Total number of admissions with AHD	IPD only	Identifies clinical severity of admissions	Minimum	Outcome	Quarterly
13	Case fatality by 10 main co morbidities * (see AHD toolkit)	Breakdown of causes of death amongst all patients diagnosed with AHD	Number of deaths by specific co morbidity	Total patients dying from AHD related co morbidities	IPD	Case fatality by co morbidity			